Tiba Biotech, BARDA Partner to Develop Therapeutics Against Influenza
Overview
Tiba Biotech LLC, a Cambridge-based preclinical biopharmaceutical company, has partnered with the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), through initiation of an EZ-BAA contract to develop groundbreaking therapeutics against influenza.
The Financial Contract
The $749,999 contract, awarded through a highly competitive review process, supports early-stage therapeutic platform development for the Flexible and Strategic Therapeutics (FASTx) program of BARDA.
This initiative aims to advance cutting-edge therapeutic platform technologies, such as RNA-mediated interference (RNAi), which could be rapidly deployed in response to emerging viral threats.
Focus
Tiba Biotech's initial focus will be on developing a prototype RNAi-based therapeutic for H1N1 influenza that targets the highly conserved viral nucleoprotein and will be delivered via Tiba's RNABL platform.
From the Lead Investigator
“We are excited to receive this BARDA award, which will advance Tiba's innovative approach to combating influenza and other viral threats,” said Dr. Jasdave Chahal, co-founder and lead investigator of the project.
“We believe our technology has the potential to transform the landscape of RNA therapeutics.”
For Combating Influenza Pandemic Threats
This initiative is an extension of Tiba's ongoing work combating influenza pandemic threats, most notably in the form of a novel multi-antigen mRNA-based H7N9 flu vaccine funded under a Phase II SBIR award from the National Institutes of Health (NIH) and ongoing collaborations with the Collaborative Influenza Vaccine Innovation Centers (CIVICs).
Project Support
This project is being supported in whole with federal funds from the Department of Health and Human Services; Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA).
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!